ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Equity Research
Zacks Rank can tell you which stocks to buy and sell. Zacks Equity Research tells you why. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

DRRX: Durect Cp - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

DURECT CP (NASD)
DRRX	2.24	0.03	(1.36%)	Vol. 8,915	10:50 ET

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations.

General Information

DURECT CORP

2 Results Way Cupertino, CA 95014 Phone: 408 777-1417 Fax: 408 777-3577 Web: www.durect.com Email: webmaster@durect.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/08/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	2.21
52 Week High	4.26
52 Week Low	1.40
Beta	1.49
20 Day Moving Average	197,704.16
Target Price Consensus	4.13

% Price Change
4 Week	-12.19
12 Week	-17.06
YTD	-38.35

% Price Change Relative to S&P 500
4 Week	-13.13
12 Week	-21.81
YTD	-48.98

Share Information
Shares Outstanding (millions)	82.20
Market Capitalization (millions)	171.80
Short Ratio	4.28
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.09
Current Year EPS Consensus Estimate	-0.36
Estimated Long-Term EPS Growth Rate	20.00
Next EPS Report Date	02/08/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	1.00
60 Days Ago	1.00
90 Days Ago	1.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	36.36%
vs. Previous Quarter	22.22%

Sales Growth
vs. Previous Year	26.29%
vs. Previous Quarter:	71.79%

Price Ratios
Price/Book	6.23
Price/Cash Flow	-
Price / Sales	6.61

ROE
09/30/09	-85.15
06/30/09	-91.30
03/31/09	-82.86

ROA
09/30/09	-40.51
06/30/09	-47.22
03/31/09	-47.60

Current Ratio
09/30/09	-
06/30/09	3.05
03/31/09	3.33

Quick Ratio
09/30/09	-
06/30/09	2.86
03/31/09	3.16

Operating Margin
09/30/09	-106.53
06/30/09	-129.14
03/31/09	-126.22

Net Margin
09/30/09	-
06/30/09	-180.06
03/31/09	-174.31

Pre-Tax Margin
09/30/09	-
06/30/09	-180.06
03/31/09	-174.31

Book Value
09/30/09	-
06/30/09	0.34
03/31/09	0.40

Inventory Turnover
09/30/09	-
06/30/09	1.10
03/31/09	1.16

Debt-to-Equity
09/30/09	-
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research